Loading...
Please wait, while we are loading the content...
First-line immune checkpoint inhibitors for extensive stage small-cell lung cancer: clinical developments and future directions.
| Content Provider | Europe PMC |
|---|---|
| Author | Ortega-Franco, A. Ackermann, C. Paz-Ares, L. Califano, R. |
| Copyright Year | 2020 |
| Journal | ESMO Open |
| Volume Number | 6 |
| PubMed Central reference number | PMC7811117 |
| Issue Number | 1 |
| PubMed reference number | 33450659 |
| e-ISSN | 20597029 |
| DOI | 10.1016/j.esmoop.2020.100003 |
| Language | English |
| Publisher | BMJ |
| Publisher Date | 2021-01-13 |
| Access Restriction | Open |
| Rights License | This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). © 2020 The Authors |
| Subject Keyword | small-cell lung cancer immune checkpoint inhibitors lung cancer atezolizumab durvalumab |
| Content Type | Text |
| Resource Type | Article |
| Subject | Oncology Cancer Research |